News

The communiqué calls on the G20 to lead the way in being truly values-driven for global impact and to operate in an environment where there is an agreement on shared values, clarity on unique values across nations, understanding of the values of difference and more.

Results from the LUCIDTY Phase 3 study suggests initial positive results for early and mild to moderate Alzheimer’s Disease

‘Integrating palliative care for older adults’ was written with ADI, The Worldwide Hospice Palliative Care Alliance (WHPCA), SANAD Hospice Lebanon and Hamad Medical Corporation (HMC).

ADI warmly welcomes the positive initial data reported today by Eisai and Biogen on the CLARITY AD global Phase 3 clinical trial of lecanemab.

ADI, alongside Newcastle University and the London School of Economics, is submitting an application to the WHO Expert Committee on the inclusion of anti-dementia medication and needs to hear from clinicians everywhere.

The project, launching 1 September, will aim to raise funds for ADI through the sale of a collection of photographs in the form of NFTs.

DY Suharya, ADI Regional director for Asia Pacific, will lead on a Values 20 (V20) work stream in preparation for the G20 summit, taking place on 15-16 November 2022.

If you are living with dementia, a carer, clinician, formal (paid) health or long-term care practitioner, we need to hear about your experience of post-diagnosis for the World Alzheimer Report 2022.